Tumor-Activated T Cells from Gastric Cancer Patients Induce the Antitumor Immune Response of T Cells via Their Antigen-Presenting Cell-Like Effects
Figure 3
Abrogation of immunosuppressive effect of CD4+CD25+ Treg cells by tumor-activated γ δ T cells. ((a) and (b)) Primary CD4+ T cells were prelabeled with CFSE as responders, and 2 × 105 cells/mL CFSE-prelabeled primary CD4+ T cells were incubated alone or coincubated with autologous CD4+CD25+ Treg cells at a ratio of 1 : 1 and/or tumor-activated γ δ T cells at a ratio of 1 : 1 : 3 in the presence of anti-CD3 mAb (1 μg/mL) and anti-CD28 mAb (1 μg/mL) with or without blocking antibodies. The same combinations were also incubated in transwell plates (c) as indicated. The proliferation of CD4+ T cells was checked on day 3 by FCM used to assess CFSE dilution. (d) 2 × 105 cells/mL CFSE-prelabeled CD4+CD25+ Treg cells were incubated alone (control) or coincubated with tumor-activated γ δ T cells at a ratio of 1 : 1. The proliferation of CD4+CD25+ Treg cells was checked on day 3 by FCM used to assess CFSE dilution. (e) 2 × 105 cells/mL tumor-activated γ δ T cells were incubated alone (control) or coincubated with CD4+CD25+ Treg cells at a ratio of 1 : 1. The apoptosis of CD4+CD25+ Treg cells was checked on day 2 by FCM. Results are representative of three independent experiments. *.
